The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2022 | Pharmacodynamic correlates and ctDNA dynamics in the NeoCOAST study
Jonathan Spicer, MD, PhD, McGill University Health Centre, Montreal, Canada, discusses the pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST study (NCT03794544). NeoCOAST is a Phase II platform study of neoadjuvant durvalumab alone or combined with oleclumab, monalizumab, or the anti-STAT3 antisense oligonucleotide davatirsen as neoadjuvant therapy in patients with resectable early-stage non-small cell lung cancer (NSCLC). Major pathological response was numerically higher in all combination arms. Expression of genes associated with NK cells increased after treatment in all arms, with the greatest increase seen in durvalumab + oleclumab and durvalumab + monalizumab arms. ctDNA analysis identified patients who had a molecular response. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
